Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment
- PMID: 8636013
- PMCID: PMC5920675
- DOI: 10.1111/j.1349-7006.1995.tb03318.x
Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment
Abstract
Recombinant mouse/human chimeric monoclonal antibody A10 (ch-A10) and its Fab fragment (ch-Fab) react with carcinoembryonic antigen on various gastrointestinal carcinomas. We performed biodistribution studies with 125I-labeled ch-A10 and ch-Fab in an antigen-positive human pancreatic carcinoma (BxPC-3) xenograft model. We also evaluated the anti-tumor effect of 131I-labeled ch-A10, and studied the detection of BxPC-3 xenografts with 123I-labeled ch-Fab in whole body scintigraphy. In comparative biodistribution studies, the tumor uptake of 125I-labeled ch-A10 was significantly greater than that of 125I-labeled ch-Fab 24 h post-injection. However, the tumor-to-blood ratio was 46.8 for ch-Fab at 24 h post-injection, while it was only 1.4 for ch-A10. Microautoradiography studies showed that ch-Fab penetrated more uniformly into the tumor nodules than did ch-A10. In mice given a therapeutic dose of 131I-labeled ch-A10, a significant inhibition of tumor growth was seen, while control 131-I-labeled human IgG did not affect tumor growth. Leukocyte toxicity was observed within 3 weeks after injection of 131I-labeled ch-A10, but leukocyte counts recovered to normal levels at 8 weeks post-injection. In whole-body scintigraphy, clear and rapid tumor imaging was obtained with 200 microCi of 123I-labeled ch-Fab 24 h post-injection. These results suggest that radioiodine-labeled chimeric A10 antibodies could potentially be useful candidates for radioimmunotherapy and radioimmunodetection of pancreatic carcinomas.
Similar articles
-
Radiolocalization of pancreatic carcinoma xenografts in nude mice with radiolabeled chimeric Fab fragments of anti-carcinoembryonic antigen monoclonal antibody A10.Pancreas. 1995 Apr;10(3):258-64. doi: 10.1097/00006676-199504000-00007. Pancreas. 1995. PMID: 7624303
-
Improved tumor detection by anti-CEA chimeric Fab oligomers with disulfide linkages in a pancreatic-carcinoma-xenograft model.Int J Cancer. 1996 Apr 10;66(2):261-7. doi: 10.1002/(SICI)1097-0215(19960410)66:2<261::AID-IJC21>3.0.CO;2-E. Int J Cancer. 1996. PMID: 8603822
-
Enhancement of tumor uptakes by stabilized Fab homo-oligomers of a chimeric monoclonal antibody against carcinoembryonic antigen.Int J Oncol. 1999 Jan;14(1):139-44. doi: 10.3892/ijo.14.1.139. Int J Oncol. 1999. PMID: 9863020
-
Carcinoembryonic antigen as a target cancer antigen for radiolabeled antibodies: prospects for cancer imaging and therapy.Tumour Biol. 1995;16(1):62-73. doi: 10.1159/000217930. Tumour Biol. 1995. PMID: 7863224 Review.
-
Human monoclonal antibodies: a tool for cancer detection in vivo.APMIS Suppl. 1999;94:5-42. doi: 10.1111/j.1600-0463.1999.tb05692.x. APMIS Suppl. 1999. PMID: 10437609 Review. No abstract available.
Cited by
-
Targeted radionuclide therapies for pancreatic cancer.Cancer Gene Ther. 2015 Aug;22(8):375-9. doi: 10.1038/cgt.2015.32. Epub 2015 Jul 31. Cancer Gene Ther. 2015. PMID: 26227823 Free PMC article. Review.
-
Radioimmunotherapy for pancreatic carcinoma using (131)I-labeled monoclonal antibody Nd2 in xenografted nude mice.Jpn J Cancer Res. 1996 Sep;87(9):977-84. doi: 10.1111/j.1349-7006.1996.tb02129.x. Jpn J Cancer Res. 1996. PMID: 8878462 Free PMC article.
References
-
- ) Begent , R. H. J. , Ledermarm , J. A. , Green , K. D. , Bagshawe , S. J. , Riggs , F. , Searle , F. , Keep , P. A. , Adam , T. , Dale , R. G , and Glaser , M. G.Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer . Br. J. Cancer , 60 , 406 – 412 ( 1989. ). - PMC - PubMed
-
- ) Breitz , H. B. , Weiden , P. L. , Vanderheyden , J.‐L. , Appelbaum , J. W. , Bjorn , M. J. , Fer , M. F. , Wolf , S. B. , Ratliff , B. A. , Seiler , C. A. , Foisie , D. C. , Fisher , D. R. , and Shoroff , R. W.Clinical experience with rhenium‐186‐labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials . J. Nucl. Med. , 33 , 1099 – 1112 ( 1992. ). - PubMed
-
- ) Carrasquillo , J. A. , Sugarbaker , P. , Colcher , D. , Reynolds , J. C. , Esteban , J. , Bryant , G. , Keenan , A. M. , Perentesis , P. , Yokoyama , K. , Simpson , D. E. , Ferroni , P. , Farkas , R. , Schlom , J. and Larson , S. M.Radioimmunoscintigra‐phy of colon cancer with iodine‐131‐labeled B72.3 monoclonal antibody. J . Nucl Med. , 29 , 1022 – 1030 ( 1988. ). - PubMed
-
- ) Halpen , S. E. , Haindl , W. , Beauregard , J. , Hagen , P. , Clutter , M. , Amox , D. , Merchant , B. , Unger , M. , Mongovi , C. , Bartholomew , R. , Jue , R. , Carlo , D. and Dillman , R.Scintigraphy with In‐ill‐labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection . Radiology , 168 , 529 – 536 ( 1988. ). - PubMed
-
- ) Brown , B. A. , Dearborn , C. B. , Drozynski , C. A. and Sands , H.Pharmacokinetics of 99mTc‐metallothionein‐B72.3 and its F(ab')2 fragment . Cancer Res. 50 ( Suppl ), 835s – 839s ( 1990. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical